Encefabol (Encephabol) Tablets 100 mg № 50

Description for Encefabol (Encephabol) Tablets 100 mg № 50

Encephabol ®
Table. n / a 100 mg, № 50

Piritinol hydrochloride 100 mg
Other ingredients: sodium karmelloza 7000, magnesium stearate, colloidal silicon dioxide, sodium carboxymethyl starch, lactose monohydrate, cellulose powder, quinoline yellow 70%, wax mountain glycol, gelatin, gum arabic, wheat flour, titanium oxide (IV), white clay, talc, sucrose.

Pharmacological properties: encephabol improves the pathologically reduced metabolism in the brain by increasing the capture and utilization of glucose, the exchange of nucleic acids, as well as increased release of acetylcholine at the synapse and the activation of cholinergic neuronal transmission. Encephabol stabilizes cell membranes and improves their function by preventing the formation of free radicals. Encephabol improves the rheological properties of blood: red blood cells increases the elasticity and fluidity of the blood, increases the ATP content in the membrane of red blood cells. In applying encephabol increases blood flow and increased oxygen consumption in ischemic areas of the brain and activates the exchange of glucose in the brain regions that previously defined ischemic damage. Encephabol contributes to the restoration of disturbed metabolic processes in nerve tissue, improve mental performance and improve memory.
After oral administration, the drug is rapidly absorbed in the digestive tract. Bioavailability averaged 85% (76-93%). Time to reach maximum concentration after oral administration of 100 mg encephabol is 30-60 minutes. Binding to plasma proteins - 20-40%. Rapidly metabolized in the liver with the formation of the main metabolites - 2-methyl-3-hydroxy-4-hydroxymethyl-5-метилмеркаптометилпиридина and 2-метилсульфинилметипиридина. Conjugated metabolites are primarily in the urine, about 5% - with the feces. The largest part of the dose was excreted within the first 4 hours after ingestion. For day 1 is derived approximately 74% of the dose. The half-life is approximately 2.5 hours penetrates through the BBB, the placental barrier in small amounts - into breast milk. If the kidney function of toxic concentrations in the body are not attained.

Indications: symptomatic treatment of chronic disorders of the brain function in dementia syndromes with the following symptoms: impaired memory and thinking, decreased concentration, fatigue, lack of incentives and motivation, affective disorders.
Primary degenerative dementia, dementia of vascular origin and mixed forms. Symptomatic treatment of chronic disorders of mental disability. Post-traumatic encephalopathy. Cerebral atherosclerosis. The consequences of encephalitis. Mental retardation, tserebrastenichesky syndrome, encephalopathy in children.

APPLICATION: dose determined individually, taking into account disease severity and patient response to treatment. The average adult dose is 200 mg - 2 tablets of 100 mg or 10 ml suspension (2 tablespoons). Multiplicity of purposes - 3 times a day.
Infants and children under 7 years are designated in the form of a suspension: infants, beginning with the third day of life - to 1 ml of suspension in the day in the morning for a month, starting from the 2 nd month of life, this dose is increased by 1 ml of each week until a daily dose until it reaches the 5 ml (1 teaspoon) 1 year old and older, depending on the evidence - 1/2-1 teaspoon suspension 1-3 times a day (from 50 to 300 mg / day) for children aged 7 years and older - 1-2 teaspoons of suspension 1-3 times a day (from 50 to 600 mg / day). Children under the age of 7 years of age or older depending on the evidence prescribed 1-2 tablets 1-3 times a day (from 50 to 600 mg / day).
Take medication during or after a meal. Tablets swallowed whole, washed down with fluid. Patients with sleep disorders, as well as children at increased excitability is not recommended to take the medication in the evening.
Clinical improvement may occur within 2-4 weeks, but the optimal effect is seen in 6-12 weeks. Duration of treatment for chronic diseases must be at least 8 weeks.
At 3 months, you should verify the presence of indications for further treatment.

Contraindications: Absolute - Hypersensitivity to piritinol to fructose (for the drug in the form of suspension); relative - a history of kidney disease, expressed by human liver and / or kidney disease; pronounced changes in the composition of peripheral blood acute autoimmune diseases such as systemic lupus erythematosus, myasthenia gravis.

SIDE EFFECTS: when using the drug for indications and recommended doses, side effects are unlikely.
Sleep disturbance, at least - irritability, headache, dizziness, fatigue, nausea, vomiting, diarrhea, at least - anorexia, taste disturbances, stomatitis, transient increase of transaminases, cholestasis, allergic reactions of varying severity (skin rash and mucous membranes itching, fever).

SPECIAL NOTES: in patients with hypersensitivity to D-penicillamine may be allergic reactions, since the latter is similar in chemical structure piritinol (thiol groups).
Piritinol crosses the placental barrier. The results of the studies did not reveal the presence of the drug teratogenic or embryotoxic action. In breast milk gets a small amount of piritinol. Decision on the possible use of the drug during pregnancy and lactation should be taken after an assessment of risk / benefit ratio.

INTERACTION: encephabol increases the severity of side effects of penicillamine, gold, drugs, and sulfasalazine.

OVERDOSE: shows increased symptom severity of side effects. Conduct gastric lavage, activated charcoal designate.

Storage conditions: at temperatures up to 20-25 ° C. Shelf life - 5 years.